Onconova Therapeutics Inc. (NASDAQ:ONTX) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.53. The business earned $1.70 million during the quarter, compared to the consensus estimate of $1.60 million. Onconova Therapeutics had a negative net margin of 102.42% and a negative return on equity of 256.32%.

Onconova Therapeutics (NASDAQ:ONTX) opened at 3.02 on Tuesday. The stock’s market capitalization is $19.15 million. The firm’s 50-day moving average is $2.63 and its 200 day moving average is $3.86. Onconova Therapeutics has a 12-month low of $2.12 and a 12-month high of $18.90.

Earnings History for Onconova Therapeutics (NASDAQ:ONTX)

Separately, Maxim Group set a $6.00 target price on shares of Onconova Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

5 Day Chart for NASDAQ:ONTX

Receive News & Stock Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related stocks with our FREE daily email newsletter.